Bergin C, O'Leary A, McCreary C, Sabra K, Mulcahy F
Department of Genitourinary Medicine, St. James's Hospital, Dublin, Ireland.
Am J Health Syst Pharm. 1995 Sep 15;52(18):2001-4. doi: 10.1093/ajhp/52.18.2001.
The efficacy of liposomal doxorubicin for treating Kaposi's sarcoma (KS) in patients infected with human immunodeficiency virus (HIV) was studied. Eight men with HIV infection and KS were to be given liposomal doxorubicin 20 mg/sq m i.v. monthly for six months and 10 mg/sq m i.v. monthly thereafter, depending on the response. They were assessed for the onset, extent, and duration of clinical response; relapse; adverse effects; development of new opportunistic infections; quality of life; and survival. Five patients had a clinical complete response (i.e., complete resolution of the manifestations of KS, as determined by physical examination but not confirmed by biopsy) and three patients had a partial response to the induction regimen of liposomal doxorubicin. Relapse occurred in all patients in whom therapy was stopped; reinstatement of therapy elicited a partial response. Neutropenia occurred in two patients; filgrastim therapy enabled the liposomal doxorubicin therapy to continue uninterrupted. Thromboembolic events developed or were suspected in three patients, although they may not have been caused by liposomal doxorubicin. Monthly i.v. administration of liposomal doxorubicin partially or completely eliminated the clinical manifestations of Kaposi's sarcoma in eight men infected with HIV.
研究了脂质体阿霉素治疗人类免疫缺陷病毒（HIV）感染患者的卡波西肉瘤（KS）的疗效。8名患有HIV感染和KS的男性患者，将每月静脉注射脂质体阿霉素20mg/平方米，共6个月，之后根据反应情况每月静脉注射10mg/平方米。对他们进行了临床反应的起始、范围和持续时间、复发、不良反应、新机会性感染的发生、生活质量和生存情况的评估。5例患者获得临床完全缓解（即通过体格检查确定KS表现完全消退，但未经活检证实），3例患者对脂质体阿霉素诱导方案有部分反应。所有停止治疗的患者均出现复发；恢复治疗引发了部分反应。2例患者出现中性粒细胞减少；非格司亭治疗使脂质体阿霉素治疗得以持续不间断。3例患者发生或疑似发生血栓栓塞事件，尽管它们可能并非由脂质体阿霉素引起。每月静脉注射脂质体阿霉素部分或完全消除了8名感染HIV男性患者的卡波西肉瘤临床表现。
